The multicohort phase II CARTITUDE 2 study investigated the use of Cilta-cel in a wide variety of MM-affected patients, including newly diagnosed (cohort E and F) and patients who had already been treated with an anti-BCMA (belantamab or BsAbs) (cohort C). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.